Conclusions
Early 3-month use of the MiniMed™ 780G system with the Guardian™ 4 Sensor in a clinical setting was safe. Most adults in the clinical and real-world setting achieved consensus glycemic targets, while many children and adolescents in both settings met recommended GMI, %TIR, and %TBR targets.